$SDST

New to The Street Broadcasts Show #716 Tonight at 6:30 PM ET on Bloomberg Television Featuring Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), Roadzen (NASDAQ:RDZN), with Special Segments from Kelsey Grammer on KAREN and Andrew

New to The Street will broadcast Show #716 tonight at 6:30 PM ET on Bloomberg Television, featuring companies Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), and Roadzen (NASDAQ:RDZN). The episode will also include special segments with Kelsey Grammer discussing his book "KAREN" and Andrew Shaw from 250DAYS.ORG. This broadcast is sponsored programming supported by national commercials from several companies, highlighting New to The Street's "Predictable Media" model.

Original reporting
Published Jan 30, 2026, 1:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 30, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
New to The Street Broadcasts Show #716 Tonight at 6:30 PM ET on Bloomberg Television Featuring Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), Roadzen (NASDAQ:RDZN), with Special Segments from Kelsey Grammer on KAREN and Andrew — source image
Decision brief

The 30-second read

$SDSTNeutralLow
01

Why it matters

While the broadcast increases visibility, it does not provide new financial data or strategic updates, limiting its impact on stock fundamentals.

02

Market read

The broadcast's primary impact is increased visibility for the featured companies, with limited immediate trading implications.

03

What to watch

Potential for increased volatility if the featured companies announce new developments following the broadcast; broader market conditions should be considered.

Timing: short-term (within 1-2 days)

Background

The program is a sponsored broadcast featuring company highlights and interviews, aimed at promoting investor awareness.

Company-level read

Ticker impact

$SDSTNeutralMedium confidence
Context

The news features Stardust Power, a NASDAQ-listed company, indicating potential relevance for traders interested in this stock.

Expected impact

Possible slight upward movement in the short term due to increased visibility; however, no significant fundamental change is indicated.

Evidence & confidence

The news is primarily promotional and does not contain new financial data or developments that would strongly influence the stock's valuation.

$BIVINeutralLow confidence
Context

BioVie's mention suggests some relevance, but as it is not the main focus of the broadcast, its impact may be limited.

Expected impact

Minimal short-term price change anticipated.

Evidence & confidence

The coverage is not centered on BioVie's recent developments or financials.

$RDZNNeutralLow confidence
Context

Roadzen's inclusion indicates some relevance, but similar to BIVI, the impact is expected to be minimal.

Expected impact

No significant movement expected.

Evidence & confidence

The news segment does not focus on Roadzen's recent performance or catalysts.

Market effects

Potential short-term interest in life sciences and technology sectors due to featured companies.

Limited regional impact, primarily affecting investor sentiment in the US markets.

Minimal; the broadcast is primarily US-focused with no significant global implications.

Counterpoint

The broadcast may be a marketing effort with limited substantive impact; traders should be cautious about overreacting.

Key entities

  • Kelsey Grammer

    Actor and author discussing his book 'KAREN'.

  • Andrew Shaw

    Representative from 250DAYS.ORG.

  • Stardust Power

    Featured company on the broadcast, listed on NASDAQ.

  • BioVie

    Featured company on the broadcast, listed on NASDAQ.

  • Roadzen

    Featured company on the broadcast, listed on NASDAQ.

Related articles

$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

$BIVIMedAI 8/10

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI) reported positive Phase 2 SUNRISE-PD results for its Parkinson's candidate bezisterim. The drug met prespecified endpoints in early-stage, untreated patients, improving blood inflammatory markers and EPNIC-15 versus placebo. Benefits were strongest in patients with higher baseline platelet counts. Safety was similar to placebo, with 39.3% adverse events vs 51.7%.

$SDSTMed

Stardust Power signs lithium supply deal with Charge CCCV

Stardust Power (NASDAQ: SDST) said it signed a non-binding Letter of Intent with battery technology firm Charge CCCV LLC (C4V) to supply battery-grade lithium carbonate from its Muskogee, Oklahoma refinery. C4V’s preliminary demand forecast calls for 3,000 MT in 2028, 10,000 MT in 2029, and 20,000 MT by 2030. Stardust noted the deal could cover much of planned output and generate billions if prices stay near current levels.

$RDZNMed

Roadzen Flat on Signing

Roadzen Inc. (NASDAQ: RDZN) said its India unit, 92% owned by Roadzen, signed a definitive deal to acquire a technology-driven managing general agent focused on short-term car rental insurance in Europe. Consideration is about $15 million, 50% at closing and 50% via a 3-year earn-out. Target revenue $18–20M and EBITDA $1.6–2M; RDZN shares were $1.22.

$RDZNMedAI 8/10

Roadzen Signs Definitive Agreement to Acquire a Leading European MGA Focused on Short-Term Car Rental Insurance

Roadzen Inc. (Nasdaq: RDZN) said it signed a definitive agreement to acquire a European technology-driven MGA focused on short-term car rental insurance. The deal, made by Roadzen’s 92%-owned India subsidiary, totals about $15 million (50% at close, 50% earn-out). The target writes ~800,000 policies annually and is expected to generate ~$18-20M revenue and ~$1.6-2M EBITDA.